Role of PCSK9 in lipid metabolism and atherosclerosis

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Xiao-Long LinMi-Hua Liu

Abstract

Elevated plasma low-density lipoprotein cholesterol (LDL-C) is an important risk factor for cardiovascular diseases. Statins are the most widely used therapy for patients with hyperlipidemia. However, a significant residual cardiovascular risk remains in some patients even after maximally tolerated statin therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new pharmacologically therapeutic target for decreasing LDL-C. PCSK9 reduces LDL intake from circulation by enhancing LDLR degradation and preventing LDLR recirculation to the cell surface. Moreover, PCSK9 inhibitors have been approved for patients with either familial hypercholesterolemia or atherosclerotic cardiovascular disease, who require additional reduction of LDL-C. In addition, PCSK9 inhibition combined with statins has been used as a new approach to help reduce LDL-C levels in patients with either statin intolerance or unattainable LDL goal. This review will discuss the emerging anti-PCSK9 therapies in the regulation of cholesterol metabolism and atherosclerosis.

References

Mar 8, 2003·Archives of Internal Medicine·Christie M BallantyneEvan A Stein
Sep 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Jay D HortonJoseph L Goldstein
Nov 8, 2003·Clinical Therapeutics·LilyAnn Jeu, Judy W M Cheng
Aug 5, 2006·The American Journal of Medicine·Andrew T YanUNKNOWN Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators
May 5, 2007·Circulation Research·Jawahar L MehtaTatsuya Sawamura
Jun 1, 2007·The Journal of Biological Chemistry·Markey C McNuttJay D Horton
Jun 21, 2007·American Journal of Physiology. Endocrinology and Metabolism·Cecilia GälmanMats Rudling
Nov 24, 2007·Journal of Lipid Research·Holly E CareskeyRobert J Konrad
Feb 5, 2008·The Journal of Biological Chemistry·Sanae KourimatePhilippe Costet
Feb 6, 2008·Proceedings of the National Academy of Sciences of the United States of America·Hyock Joo KwonJohann Deisenhofer
Mar 22, 2008·Atherosclerosis·Jamie CameronKnut Erik Berge
Jun 13, 2008·Lipids in Health and Disease·Janice MayneMichel Chrétien
Jul 22, 2008·Biochemical and Biophysical Research Communications·Kenneth R FeingoldCarl Grunfeld
Aug 5, 2008·Biochemical and Biophysical Research Communications·LiXin ShanJoseph A Hedrick
Aug 13, 2008·Proceedings of the National Academy of Sciences of the United States of America·Maria Frank-KamenetskyKevin Fitzgerald
Feb 20, 2009·The Journal of Biological Chemistry·Markey C McNuttThomas A Lagace
Mar 7, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Cédric Le MayPhilippe Costet
May 16, 2009·Proceedings of the National Academy of Sciences of the United States of America·Joyce C Y ChanSimon M Jackson
Jul 3, 2009·Journal of Lipid Research·Geneviève DubucJean Davignon
Jul 22, 2009·Atherosclerosis·Giuseppe Danilo NorataAlberico Luigi Catapano
Jun 18, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Omar N AkramGilles Lambert
Aug 19, 2010·Journal of Lipid Research·Jeffrey D Browning, Jay D Horton
Jan 26, 2011·Journal of Lipid Research·Brandon AsonNelly A Kuklin
Jul 22, 2011·Atherosclerosis·Si GaoSuowen Xu
Aug 19, 2011·Molecular and Cellular Biochemistry·Chun-Yan WuLu-Shan Liu
Nov 24, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Marie W LindholmTroels Koch

❮ Previous
Next ❯

Citations

Feb 6, 2020·Current Opinion in Endocrinology, Diabetes, and Obesity·Raul C MaranhãoFatima R Freitas
Dec 14, 2018·Oxidative Medicine and Cellular Longevity·Li LuXiaomei Guo
May 28, 2020·Acta Pharmacologica Sinica·Le-Chun OuJin-Wei Tian
Jan 29, 2021·Indian Journal of Clinical Biochemistry : IJCB·Murooj L MajeedHind F Mahdi
Jun 24, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yihan ZhaoDazhuo Shi
May 7, 2021·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jennifer HardyRebecca F Goldfaden
Jun 3, 2021·International Journal of Molecular Sciences·Eunhye Ji, Sahmin Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Related Papers

Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
Ahmet AvciBülent Behlül Altunkeser
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Michel Farnier
Expert Opinion on Therapeutic Targets
Christopher J Duff, Nigel M Hooper
Current Pharmaceutical Design
Maciej BanachEsma R Isenovic
© 2022 Meta ULC. All rights reserved